- Home
- VABK vs NGEN Comparison
VABK vs NGEN Comparison
Compare VABK & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | VABK | NGEN |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.4M | 197.5M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | VABK | NGEN |
|---|---|---|
| Price | $44.40 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 7.0K | ★ 873.0K |
| Earning Date | 04-23-2026 | 04-02-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 12.70 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.60 | $1.70 |
| 52 Week High | $48.58 | $5.93 |
Technical Indicators
Market Signals| Indicator | VABK | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 46.23 |
| Support Level | $38.18 | $1.70 |
| Resistance Level | $48.58 | $2.35 |
| Average True Range (ATR) | 1.04 | 0.17 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 37.66 | 64.35 |
Price Performance
Historical ComparisonAbout VABK Virginia National Bankshares Corporation
Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.